Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines

NCT01772524 is registered in ClinicalTrials.gov with Alder Biopharmaceuticals, Inc. as lead sponsor.

NCT NCT01772524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01772524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 1b Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of a Single Dose of ALD403 Administered Intravenously in Patients With Frequent Episodic Migraines
Lead sponsor
Alder Biopharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2013
Completion date
February 28, 2014
Enrollment
163 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

migraine